Keytruda Shows Promise in Patients with Merkel Cell Carcinoma, A Rare Form of Skin Cancer

merck_logo_biotechjobs-300x87

April 19, 2016

KEYTRUDA is a medicine that contains the humanized antibody pembrolizumab and it treats cancer types such as melanoma and lung cancer by working with the immune system. A new study showed that more than half of the patients responded to a rare but aggressive form of skin cancer known as Merkel cell carcinoma.

It was a small clinical trial in which 26 patients were given the treatment with pembrolizumab and the objective response rate among the 25 patients who could be evaluated was 56%. 4 patients showed complete response and 10 patients had a partial response.screencapture - cancer
About 80 percent of Merkel cell carcinoma are caused by the viral infection by Merkel cell polyomavirus (MCPyV). This study is very important as it demonstrates that virus-driven cancers may be treated with immunotherapy. Merkel cell carcinoma may also be caused by the exposure to ultraviolet radiation from the sun. Merkel cell carcinoma is more aggressive than melanoma and is several times more lethal.
Right now there’s no drug approved for Merkel cell carcinoma but this study has shed a light on the new action of pembrolizumab, more studies and evidence are required for the better understanding of important questions, such as how long patients should be treated after responding, which patients are most likely to respond to immunotherapy, whether other virus-associated cancers can be treated with immunotherapy. These are some open questions that require more research and findings.
This study was funded by the National Cancer Institute and Merck.

Reference:

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem, M.D., Ph.D., Shailender Bhatia, M.D., Evan J. Lipson, M.D., Ragini R. Kudchadkar, M.D., Natalie J. Miller, B.A., Lakshmanan Annamalai, D.V.M., Ph.D, Sneha Berry, M.S., Elliot K. Chartash, M.D., Adil Daud, M.B., B.S., Steven P. Fling, Ph.D., Philip A. Friedlander, M.D., Harriet M. Kluger, M.D., Holbrook E. Kohrt, M.D., Ph.D., Lisa Lundgren, M.S., Kim Margolin, M.D., Alan Mitchell, M.Sc., Thomas Olencki, D.O., Drew M. Pardoll, M.D., Ph.D., Sunil A. Reddy, M.D., Erica M. Shantha, M.D., William H. Sharfman, M.D., Elad Sharon, M.D., M.P.H., Lynn R. Shemanski, Ph.D., Michi M. Shinohara, M.D., Joel C. Sunshine, M.D., Ph.D., Janis M. Taube, M.D., John A. Thompson, M.D., Steven M. Townson, Ph.D., Jennifer H. Yearley, D.V.M., Ph.D., Suzanne L. Topalian, M.D., and Martin A. Cheever, M.D.
April 19, 2016 DOI: 10.1056/NEJMoa1603702

Advertisements

2 thoughts on “Keytruda Shows Promise in Patients with Merkel Cell Carcinoma, A Rare Form of Skin Cancer

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s